semaglutide cardiovascular outcomes 2025 news today Population‐level impact of semaglutide 2.4 mg in patients with obesity Cardiovascular Disease | Ozempic® (semaglutide)

Reduced energy expenditure: Hypothyroidism is associated with decreased thermogenesis and overall energy expenditure

Strategy 2: Fermentable Fiber for SCFA Production The Science: L-cells express receptors for short-chain fatty acids (SCFAs)particularly butyrate and propionate

GLP-1 medications such as semaglutide (Ozempic) and tirzepatide (Mounjaro) are powerful tools for weight loss

These medications are not recommended for people who have been diagnosed with pancreatitis or type 1 diabetes, are under 18 years of age, or are pregnant or breastfeeding

Although Retatrutide is not yet available, it underscores the continuous evolution of weight loss therapies

JAMA, 330(20), 20002015